Fig. 1From: An open-label study to evaluate biomarkers and safety in systemic sclerosis patients treated with paquinimodPlasma levels of paquinimod in each individual patient were analyzed at weeks 2, 4 and 8, and at follow-up week 12, by using LC-MS/MSBack to article page